Jinarc is a medicine used to treat adults with autosomal dominant polycystic kidney disease. This is an inherited condition in which numerous fluid\-filled cysts develop in the kidneys, which eventually affect kidney function and can cause the kidneys to fail. Jinarc is for use in patients with normal to moderately reduced kidney function at the beginning of treatment with Jinarc and whose disease is progressing rapidly. Jinarc contains the active substance tolvaptan.
Therapeutic Indication
Jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.
Therapeutic Area (MeSH)
ATC Code
C03XA01
ATC Item
N/A
Pharmacotherapeutic Group
Diuretics
Active Substance (Summary)
INN / Common Names
EMA Name
Jinarc
Medicine Name
Jinarc
Aliases
N/ANo risk management plan link.
